Ana Graf is listening to the nutrition. The leader of the global NeuroScience programs at Pharmarten Novartis had high hopes for a new Alzheimer's drug on behalf of Umibecestat. However, they have resolved themselves in the air.
"We have canceled the study program because the analysis of the data shows: The risk of treatment is greater than the benefit of the problems. who have significantly impaired cognitive abilities. "
Not only that the potential Alzheimer's drug Umibecestat showed no effect in large clinical studies. Including the substance, the brain functions of the proband even affect it. Both ongoing studies with Umibecestat were therefore terminated as soon as possible. The other hope-bearers also appeared shortly before admission. Your names: Bapineuzumab, Solanezumab, Crenezumab and Aducanumab. The researchers are ruthless as to why extravagant substances end up with Alzheimer's but not the expected effect.
"Unfortunately, we do not know yet. Neither we here at Novartis nor the other professionals in the field. But we work there, who We want to find out who came to these results. "
If the affected person is no longer able to read the clock time, this is an indication for dementia or Alzheimer's (image stock & people)
Only four medicines are available Worked on the market
Following claims by the US Pharmaceutical Companies, 146 hires to treat Alzheimer's from 1998 to 2017. Only four drugs are available on the market, and those who can relieve the symptoms of the disease can cure Alzheimer's
Dabei had proclaimed Barack Obama in 2012 until Alzheimer's would be defeated by the year 2025. But seven years later, humanity is no further step in the fight against the debilitating forgetfulness. The various companies have spent billions to spend The Pharmariese Pfizer seeks 2018, which has consisted and put all its own Alzheimer's research projects in place over a venture capital fund the companies continue to develop innovative treatment approaches in the development.
In 2012, then-US President Obama fully announced, by 2025, Alzheimer's defeated (AP / Alyssa Pointer)
It is a substantial nutritional introduction"
First of all, one must say that the industry's commitment to Alzheimer's is high. Most large pharma companies and many small Alzheimer's programs have been falling for years, years have fallen. Nowadays, however, there is a substantial diet. I do not believe that this industry is basically withdrawing from the field. "
Frank Jessen is the chief physician of the Clinic of Psychiatry and Psychotherapy at the University Clinic of Cologne and one of the leading Alzheimer's researchers in Germany. Many of the recently failed doctors he said, she said, but it was easy to say.
Exactly the Novartis preparation Umibecestat, which harms more than useful, put these substances into the protein amyloid ß. In Alzheimer's patients it is a defect Structure and attaches to the brain into so-called plaques, which in the development of substances that are present, either prevent the formation of amyloid ß or directly seize it.
that research is on the right path.
"You ask yourself at the moment: Is that right at all a concept "
" It did work in itself, so the plaques became less. But the disease is progressing and you are asking yourself: Is that the right concept at all? Or are these amyloid peptides just a by-product of Alzheimer's disease? And there is no such thing as the cause of neurodegeneration we are observing. "
Pharma companies now have to think about and intensify research into alternative therapy approaches. Another failed protein, the so-called tau protein, could signal a new attack point. which amyloid-ß occurs more frequently in Alzheimer's patients than in healthy people.
"There are present investigations into whether the removal of Tau proteins can help in Alzheimer's disease. This is one possibility.
The other is that it excludes other pharmacological possibilities that improve the functioning of the nervous systems, neural networks. " increase – a fuel that is important for memory and attention. Although these symptoms have been alleviated, the disease is progressing further.
"It is now possible to change whether further fuels could be altered in a way that their effect could be improved. that affect Alzheimer's disease. "
Worldwide run currently 247 Alzheimer's drug studies
Worldwide run according to the" clinicaltrials "study database of 247 clinical drug studies in addition to Alzheimer's drug trials, 53 of which are currently being studied. However, the bulk of these phase 3 studies are still investigating substances used in Am employing yloid-β protein. Since this class of substances did not fulfill expectations until long, no further setbacks were excluded.
In a early phase of development, they found employment that should work against neuroinflammation in Alzheimer's.
"It has been observed that in the brain of Alzheimer's patients some inflammatory activity or change is occurring. Research in recent years, both in the United States and even in Europe, has increased steadily.
Currently no prospect of healing
But to bring a drug into the market, all pharmaceuticals had to be consumed only for one substance. This risk cannot be taken by any state of the world. The commitment of the pharmaceutical companies is therefore further advanced. And Frank Jessen of the Cologne Unique Clinic is optimistic that, despite the loss of the past years, he will not lie in the field. Accordingly, Alzheimer's said a lot of meaningful illness.
"So we see multifaceted activity. But in fact, one must say: The next year probably no new drug will be provided to patients!"